Health Care & Life Sciences » Biotechnology | Genocea Biosciences Inc.

Genocea Biosciences Inc.

Genocea Biosciences Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
86.63 M
Public Float
57.86 M
Genocea Biosciences Inc.
Stock Exchange NASDAQ Stock Market
EPS
$2.32
Market Cap
$94.03 M
Shares Outstanding
24.55 M
Public Float
26.44 M

Profile

Address
Cambridge Discovery Park
Cambridge Massachusetts 02140
United States
Employees -
Website http://www.genocea.com
Updated 07/08/2019
Genocea Biosciences engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine.

Financials

View All
Created with Highcharts 5.0.14Genocea Biosciences Inc.Net Income. Fiscal year is January-December. All values USD Thousands.22 41122 41135 47635 47642 48342 48349 57349 57356 71056 71027 81127 811201320142015201620172018010k20k30k40k50k60k
Created with Highcharts 5.0.14Genocea Biosciences Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.0000670670235235001 0881 088201320142015201620172018025050075010001250

William D. Clark
President, Chief Executive Officer & Director
George R. Siber
Executive Director